Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy-Reference-Cited by-同舟云学术

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy

Published:2023-09-10 Issue:18 Volume:15 Page:4503
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Dal Collo Giada¹^ORCID,Takam Kamga Paul²^ORCID

Affiliation:

1. Department of Immunology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands

2. EA4340 BECCOH, Université Paris-Saclay, UVSQ92100 Boulogne-Billancourt, France

Abstract

Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/18/4503/pdf

Reference41 articles.

1. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma;Lipson;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2011

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

4. Mehlman, C., Takam Kamga, P., Costantini, A., Julié, C., Dumenil, C., Dumoulin, J., Ouaknine, J., Giraud, V., Chinet, T., and Emile, J.-F. (2021). Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancers, 13.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring novel immunotherapy biomarker candidates induced by cancer deformation;PLOS ONE;2024-05-14